Drug Trial Radar · NCT02066402
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Last checked: Nov 20, 2026Latest source record: Jun 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
598
Actual
Start
Mar 4, 2014
Primary completion
Mar 6, 2016
Study completion Apr 18, 2016
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Feb 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is aimed to evaluate the efficacy and safety between Tedizolid 200mg daily (intra venous) I.V. to oral for 6-day treatment compared with that of Linezolid 600mg twice daily I.V. to oral for 10-day treatment Acute Bacterial Skin and skin structure infection (ABSSSI).This is a double-blind, randomized, active control, 7-10days treatment for all subjects.
Conditions
- Bacterial Infections
Interventions
Tedizolid (BAY119-2631)Drug
50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
Placebo Tedizolid (BAY119-2631)Drug
50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
LinezolidDrug
50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
Placebo LinezolidDrug
50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Early Clinical Response at 48-72 Hours After the First Infusion of Study Drug in the ITT Analysis Set.Time frame: Baseline and 48-72 hours visit
Locations
55 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Chula Vista, California
Site not named
La Mesa, California
Site not named
Oceanside, California
Site not named
Las Vegas, Nevada
Site not named
Teaneck, New Jersey
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Chongqing, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Shanghai, China
Site not named
Tianjin, China
Site not named
Tianjin, China
Site not named
Wuhu, Anhui, China
Site not named
Fuzhou, Fujian, China
Site not named
Guangzhou, Guangdong, China
Site not named
Guangzhou, Guangdong, China
Site not named
Wuhan, Hubei, China
Site not named
Changsha, Hunan, China
Site not named
Changsha, Hunan, China
Site not named
Changsha, Hunan, China
Site not named
Nanjing, Jiangsu, China
Site not named
Nanjing, Jiangsu, China
Site not named
Suzhou, Jiangsu, China
Site not named
Wuxi, Jiangsu, China
Site not named
Changchun, Jilin, China
Site not named
Dalian, Liaoning, China
Site not named
Shenyang, Liaoning, China
Site not named
Shenyang, Liaoning, China
Site not named
Xi'an, Shaanxi, China
Site not named
Xi'an, Shaanxi, China
Site not named
Jinan, Shandong, China
Site not named
Taiyuan, Shanxi, China
Site not named
Chengdu, Sichuan, China
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.